Teva Pharmaceutical Industries Limited (TLV:TEVA)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
8,438.00
+203.00 (2.47%)
Nov 13, 2025, 5:26 PM IDT
2.47%
Market Cap94.03B
Revenue (ttm)55.55B
Net Income (ttm)2.36B
Shares Outn/a
EPS (ttm)2.04
PE Ratio39.83
Forward PE9.56
Dividendn/a
Ex-Dividend Daten/a
Volume1,661,810
Average Volume2,235,685
Open8,236.00
Previous Close8,235.00
Day's Range8,211.00 - 8,480.00
52-Week Range4,865.00 - 8,480.00
Beta0.70
RSI83.22
Earnings DateNov 5, 2025

About Popular

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]

Sector Healthcare
Founded 1901
Employees 35,686
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol TEVA
Full Company Profile

Financial Performance

In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.

Financial numbers in USD Financial Statements

News

Gleview Capital Adjusts Portfolio, Increases Stake in Teva Pharmaceutical (TEVA)

Gleview Capital Adjusts Portfolio, Increases Stake in Teva Pharmaceutical (TEVA)

15 hours ago - GuruFocus

Generics Stalwart Teva Has Turned A Corner In Its Specialty Medicines Business

See how Teva Pharmaceutical Industries Limited's growth strategy and focus on specialty medicines are driving a turnaround. Click for more on TEVA and its earnings.

22 hours ago - Seeking Alpha

Insider Selling: Amir Weiss Unloads $300K Of Teva Pharmaceutical Indus Stock

A substantial insider sell was reported on November 10, by Amir Weiss , Chief Accounting Officer at Teva Pharmaceutical Indus (NYSE: TEVA), based on the recent SEC filing. What Happened: A Form 4 fil...

3 days ago - Benzinga

Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today

Teva Pharmaceutical Indus (NYSE: TEVA) has outperformed the market over the past 5 years by 6.92% on an annualized basis producing an average annual return of 20.65%. Currently, Teva Pharmaceutical I...

4 days ago - Benzinga

Price Over Earnings Overview: Teva Pharmaceutical Indus

In the current session, the stock is trading at $24.04, after a 0.29% spike. Over the past month, Teva Pharmaceutical Indus Inc. (NYSE: TEVA) stock increased by 19.72% , and in the past year, by 40.7...

4 days ago - Benzinga

Teva (TEVA) Reveals Promising Data on AUSTEDO for Tardive Dyskinesia

Teva (TEVA) Reveals Promising Data on AUSTEDO for Tardive Dyskinesia

7 days ago - GuruFocus

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

PARSIPPANY, N.J., and TEL AVIV, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the prese...

7 days ago - GlobeNewsWire

Decoding Teva Pharmaceutical Industries Ltd (TEVA): A Strategic SWOT Insight

Decoding Teva Pharmaceutical Industries Ltd (TEVA): A Strategic SWOT Insight

8 days ago - GuruFocus

JP Morgan Raises Teva Pharmaceutical (TEVA) Price Target to $28 | TEVA Stock News

JP Morgan Raises Teva Pharmaceutical (TEVA) Price Target to $28 | TEVA Stock News

8 days ago - GuruFocus

TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up

Teva stock jumps after third-quarter earnings and revenues top estimates, driven by robust Austedo sales as well as U.S. generics growth.

8 days ago - Nasdaq

Why Teva Pharmaceutical Stock Rocked the Market Today

The company delivered a convincing pair of beats in its third-quarter earnings report.

9 days ago - The Motley Fool

Teva Pharmaceutical Industries Ltd (TEVA) Q3 2025 Earnings Call Highlights: Strong Growth ...

Teva Pharmaceutical Industries Ltd (TEVA) Q3 2025 Earnings Call Highlights: Strong Growth Amidst Market Challenges

9 days ago - GuruFocus

Teva Pharmaceutical (TEVA) Reports Strong Q3 2025 Growth

Teva Pharmaceutical (TEVA) Reports Strong Q3 2025 Growth

9 days ago - GuruFocus

Q3 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript

Q3 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript

9 days ago - GuruFocus

Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working

Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent quarter, what's driving growth, and much more.

9 days ago - CNBC Television

Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working

Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent quarter, what's driving growth, and much more.

9 days ago - CNBC

Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were higher, with the Nasdaq Composite gaining more than 200 points on Wednesday. Shares of Johnson Controls International PLC (NYSE: JCI) rose sharply during Wednesday's session after th...

9 days ago - Benzinga

Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported its third-quarter 2025 financial results on Wednesday, with total revenue of $4.48 billion, beating analysts' expectations of $4.35 billion, ...

9 days ago - Benzinga

Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its third-quarter 2025 financial results on Wednesday, with total revenue of $4.48 billion, beating analysts' expectations of $4.35 billion, ac...

9 days ago - Benzinga

Teva (TEVA) Stock Surges Over 18% with Impressive Gains

Teva (TEVA) Stock Surges Over 18% with Impressive Gains

9 days ago - GuruFocus

Teva Pharmaceuticals stock surges 12% as branded drug sales outperform

Teva Pharmaceutical Industries Ltd. stock rose 12% after the company reported stronger-than-expected third-quarter results, buoyed by robust growth in its branded drug portfolio.

10 days ago - Invezz